about
Dendritic cell vaccines for brain tumorsEvaluation of in vivo labelled dendritic cell migration in cancer patientsT-cell clonotypes in cancerTumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccinesDendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiencyImmune Cells in Cancer Therapy and Drug DeliveryInduced Pluripotent Stem Cell as a New Source for Cancer ImmunotherapyHigh-risk corneal allografts: A therapeutic challengePathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationCurrent status and perspectives of immune-based therapies for hepatocellular carcinomaRNA-Based Vaccines in Cancer ImmunotherapyImmunotherapy advances for glioblastomaLung cancer vaccinesTumor cell lysates as immunogenic sources for cancer vaccine designImmunotherapy for Bone and Soft Tissue SarcomasProspects for exosomes in immunotherapy of cancerImmunosuppressive networks in the tumour environment and their therapeutic relevancePre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cellsInduction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling.Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo.Langerhans cells as targets for immunotherapy against skin cancer.A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.Toll-like receptor agonists: are they good adjuvants?Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Vaccines against cancer: Despite setbacks, attempts to harness the patient's immune system to fight tumor cells show promise in clinical trialsCD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.Translating tumor antigens into cancer vaccinesPhase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.Dendritic cell subsets in health and disease.Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytesHydrogels and scaffolds for immunomodulationISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.RAB8A a new biomarker for endometrial cancer?Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patientsEx vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantationEffects of dendritic cells from hepatitis B virus transgenic mice-stimulated autologous lymphocytes on hepatitis B virus replication: a study on the impact of specific sensitized effector cells on in vitro virus replicationGene therapy and targeted toxins for glioma.
P2860
Q24641823-DA1FF839-D226-495C-B886-DDB81CC339E4Q24799742-9EB80666-69F6-4D4D-B053-E1F55EEC104BQ24803891-50CD2334-45A3-4491-A08A-B8EF60C013A7Q24804837-1185F907-C921-4CC9-BDD3-D3DD1D6C26A9Q24810259-FD2A3337-9D8A-4FC9-AA6B-F9FBBC8BFB4BQ26747061-ED55985B-C9C0-498C-952D-0F77A87F3138Q26750579-7E503A04-7F2B-470E-9D7A-0BBE98B424F5Q26751483-4C8CFA77-3939-44FB-AEF6-FF3F74152001Q26765345-8C5A11A5-E970-40FA-A988-8338955D78F5Q26772326-BABAA701-2476-4EE3-8BB7-BE712A3F394CQ26776028-75616202-8720-4127-A7F5-857DAA5F3B15Q26866513-4A1A78E0-7C4D-4768-A2C1-6E0D2283BAD7Q27014375-15D31F39-268F-4C54-A2C2-0FEAAA235C4EQ28083469-F00CD6A5-C0F8-4A88-9C0E-423E47AAE0DAQ28088363-36F29A21-7B71-4030-981A-79044E8EA9FAQ28248098-878BA5AC-767F-477B-BFBB-2B185479B155Q29619244-535609FB-239D-4BB4-9F8F-6C6AE4EDF500Q30409053-A02E3625-A58C-489B-B78A-BF6A2CE74664Q30478868-FCD82CF0-1AEB-4D32-B675-D7AE42137931Q30587203-0D0C4B70-F1A5-437F-8F17-1D9DEB924354Q33788255-82BBA8E4-E9B3-4619-9ED9-1DF20A33BB6EQ34009436-B54E9C7D-01A4-4B9C-909B-54F0C0D9B7B0Q34015759-7B80C4AC-0BCC-4633-98F6-659EDFC47BEFQ34067537-6F912950-8E8D-46C2-92D3-6315C0D532C0Q34202646-EE6A7A05-0156-45AB-A851-773A0FF8BE60Q34328457-6FB66AE0-509F-40C5-AE39-534AF1DC06C3Q34407946-110121C7-359C-4A6E-BBA0-23F5B8A0012CQ34409830-B66B69A0-C916-4A01-9B42-13CB27DB141CQ34484042-E8DB3ABB-A520-456B-9E17-AC5B69DA729EQ34528054-7B94F5FE-CC01-4DB5-B9DD-D52C3265412CQ34582889-BFF3B4B1-6142-4AD0-9298-F84DC224CE84Q34646946-39F8BC2D-55B9-4DAB-B563-43186AF9971EQ34658123-F8639A5E-A52A-4F8B-BC31-EEE5A4450C27Q34725541-7A0EEF06-3582-402C-B4A4-3EE7535FBA85Q34848159-ADECCB2A-88E7-4317-A692-BD78F5B05B27Q34897971-01BDD4EF-5D29-4CFE-9FD5-4B2299F440FBQ35021619-1C8C67F1-2112-4F31-BD4C-52A6501D947DQ35085385-C14BB944-A163-412D-B04E-2262B4A4B548Q35097598-86E7FB7F-4AE4-4735-8DC3-5C675EC7DF2CQ35118933-65128860-CC97-479D-B4C1-292A9A07D97E
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The use of dendritic cells in cancer immunotherapy.
@ast
The use of dendritic cells in cancer immunotherapy.
@en
type
label
The use of dendritic cells in cancer immunotherapy.
@ast
The use of dendritic cells in cancer immunotherapy.
@en
prefLabel
The use of dendritic cells in cancer immunotherapy.
@ast
The use of dendritic cells in cancer immunotherapy.
@en
P2093
P1476
The use of dendritic cells in cancer immunotherapy.
@en
P2093
Beatrice Schuler-Thurner
Gerold Schuler
Ralph M Steinman
P304
P356
10.1016/S0952-7915(03)00015-3
P577
2003-04-01T00:00:00Z